Abstract
Purpose: Only an endophytic growth pattern in juxtapapillary retinal hemangioblastoma (JRH) is an indication for surgical treatment, but classification of growth types is difficult using conventional imaging techniques. This case report describes the use of optical coherence tomography angiography (OCT-A) features for classification and treatment follow-up in a case with JRH. Observations: The JRH of this patient was easily detected with two different OCT-A methods in both en-face and cross-sectional B-scan images, and was classified as a sessile growth type. This growth type excluded the treatment option of vitreoretinal surgery with excision of the lesion or ligation of the feeder vessels. The patient was treated multiple times with intravitreal bevacizumab. Treatment follow-up with OCT-A initially revealed a stable extent of the JRH, with some slight flow deviations in en-face visualization, followed by a period of progressive growth of the lesion. Conclusions: OCT-A revealed the depth localization of the JRH and seems to be a valuable tool for JRH classification. Detailed classification may be useful when surgery is considered as a treatment strategy. Furthermore, treatment follow-up is possible with OCT-A, although imaging artifacts should be taken into account.
Original language | English |
---|---|
Article number | 100472 |
Journal | American Journal of Ophthalmology Case Reports |
Volume | 15 |
DOIs | |
Publication status | Published - 1 Sept 2019 |
Funding
The patient signed an informed consent of the Exploratory flow-OCT study. The study was approved by the local internal review board of the Rotterdam Eye Hospital and the Medical Ethical Committee of the Erasmus University Hospital (Rotterdam, the Netherlands). This work was supported by Health-Holland, Top Sector Life Sciences & Health ( LSHM16001 ), Heidelberg Engineering , the Dutch Technology Foundation STW ( 12822 ) and the Netherlands Organisation for Health Research and Development ZonMW ( 91212061 ). - LS, VD, JdB and KV: Financial support (Heidelberg Engineering); - JdB: Patent (Massachusetts General Hospital); - MvV: Recipient (Bayer NL, Abbvie NL, Novartis NL, Allergan NL); - KvO and JdJ: no financial disclosures.
Funders | Funder number |
---|---|
Health-Holland | |
Netherlands Organisation for Health Research and Development ZonMW | 91212061 |
Top Sector Life Sciences & Health | LSHM16001 |
Stichting voor de Technische Wetenschappen | 12822 |
Heidelberg Engineering |
Keywords
- Doppler OCT
- Intravitreal bevacizumab
- Juxtapapillary retinal hemangioblastoma
- Optical coherence tomography angiography
- Sessile